GH — Guardant Health Cashflow Statement
0.000.00%
- $8.16bn
- $8.65bn
- $739.02m
- 43
- 23
- 87
- 49
Annual cashflow statement for Guardant Health, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -246 | -385 | -655 | -479 | -436 |
| Depreciation | |||||
| Non-Cash Items | 174 | 194 | 248 | 57.8 | 215 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -47.7 | -40.5 | 61.6 | 53.8 | -60.9 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -104 | -209 | -309 | -325 | -240 |
| Capital Expenditures | -54.1 | -75 | -77.5 | -20.5 | -35.1 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | -563 | 11.9 | 227 | 861 | -226 |
| Sale of Business | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -617 | -63.2 | 150 | 840 | -261 |
| Financing Cash Flow Items | -94.6 | -83.8 | -201 | -26.3 | -15.8 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 1,410 | -66.8 | -189 | 477 | -0.996 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 690 | -341 | -350 | 992 | -504 |